Who is sponsoring NCT04640402?

NCT04640402 is sponsored by Jiangsu Province Centers for Disease Control and Prevention.

What drugs are being tested in NCT04640402?

Interventions in NCT04640402: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen, Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen, High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen, High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen, Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen, Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen, High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen, High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen, Low-dose placebo (18-59 years) & Two dose regimen, Low-dose placebo (18-59 years) & Three dose regimen, High-dose placebo (18-59 years) & Two dose regimen, High-dose placebo (18-59 years) & Three dose regimen, Low-dose placebo (60-85 years) & Two dose regimen, Low-dose placebo (60-85 years) & Three dose regimen, High-dose placebo (60-85 years) & Two dose regimen, High-dose placebo (60-85 years) & Three dose regimen.

Is NCT04640402 still recruiting?

NCT04640402 is currently completed. Last updated 1 June 2022.

Last reviewed 2022-06-01 · How we verify

NCT04640402

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

Completed Phase 2 Last updated 1 June 2022

What this trial tests

Phase 2 trial testing Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen in COVID-19 in 960 participants. Completed in 23 November 2021.

Timeline

17 November 2020

Primary endpoint
18 February 2021

23 November 2021

Quick facts

Lead sponsor	Jiangsu Province Centers for Disease Control and Prevention
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	960
Start date	17 November 2020
Primary completion	18 February 2021
Estimated completion	23 November 2021
Sites	1 location across China

Drugs / interventions tested

Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen — full drug profile →
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen — full drug profile →
Low-dose placebo (18-59 years) & Two dose regimen
Low-dose placebo (18-59 years) & Three dose regimen — full drug profile →
High-dose placebo (18-59 years) & Two dose regimen
High-dose placebo (18-59 years) & Three dose regimen
Low-dose placebo (60-85 years) & Two dose regimen
Low-dose placebo (60-85 years) & Three dose regimen — full drug profile →
High-dose placebo (60-85 years) & Two dose regimen — full drug profile →
High-dose placebo (60-85 years) & Three dose regimen

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Jiangsu Province Centers for Disease Control and Prevention — full company profile →

Who can join

Adults 18 to 85, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) with different immunization procedures (0, 21 days and 0, 14, 28 days) and doses (20μg/40μg).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

COVID-19 vaccines: rapid development, implications, challenges and future prospects.
Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. · · 2021 · cited 240× · PMID 33677814 · DOI 10.1007/s13577-021-00512-4
Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
Antibodies and Vaccines Target RBD of SARS-CoV-2.
Min L, Sun Q. · · 2021 · cited 123× · PMID 33968996 · DOI 10.3389/fmolb.2021.671633
COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials.
Yan ZP, Yang M, Lai CL. · · 2021 · cited 89× · PMID 33923054 · DOI 10.3390/ph14050406
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
Meng FY, Gao F, Jia SY, Wu XH, et al · · 2021 · cited 26× · PMID 34267185 · DOI 10.1038/s41392-021-00692-3
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.
Scarabel L, Guardascione M, Dal Bo M, Toffoli G. · · 2021 · cited 12× · PMID 33476760 · DOI 10.1016/j.ijid.2021.01.035
A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2.
Damodharan K, Arumugam GS, Ganesan S, Doble M, et al · · 2021 · cited 7× · PMID 35479882 · DOI 10.1039/d0ra09668g
Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.
Bandaru R, Rout SR, Kamble OS, Samal SK, et al · · 2022 · cited 4× · PMID 35437418 · DOI 10.1016/j.procbio.2022.04.011

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Jiangsu Province Centers for Disease Control and Prevention trials

Trials by the same sponsor.

NCT07530679 — Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vacc · NA · not yet recruiting
NCT07232745 — Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine · Phase 4 · active not recruiting
NCT06609811 — The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuat · Phase 4 · completed
NCT07035054 — Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine · Phase 2 · completed
NCT07025876 — PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04640402 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Province Centers for Disease Control and Prevention
Last refreshed: 1 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04640402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing